RECRUITING

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Talk to us

Conditions

End of LifeCancerCarcinomaLung NeoplasmsCarcinoma, Non-Small-Cell LungMelanomaPancreatic NeoplasmsSarcomaOvarian NeoplasmsCarcinoma, Ovarian EpithelialStomach NeoplasmsGlioblastomaRectal NeoplasmsColonic NeoplasmsEsophageal NeoplasmsBreast NeoplasmsCarcinoma, Renal CellSkin NeoplasmsSmall Cell Lung CarcinomaOsteosarcomaMyelodysplastic SyndromesDisease ProgressionNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract DiseasesUrogenital NeoplasmsCarcinoma, Bronchogenic

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.

Official Title

Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Quick Facts

Study Start:2022-06-24
Study Completion:2028-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05297734

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Newly diagnosed patients with solid tumor cancer diagnosis or recurrence of the disease.
  2. 2. Patients must have the ability to understand and willingness to provide verbal consent.
  3. 3. Participants must speak English, Spanish, Chinese, or Vietnamese.
  1. 1. Inability to consent to the study
  2. 2. Plans to change oncologist within 12 months
  3. 3. Employed by the practice site
  4. 4. Patients who anticipate moving from the area within 12 months

Contacts and Locations

Study Contact

Manali I Patel, MD MPH MS
CONTACT
6507234000
manalip@stanford.edu

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35294
United States
University of South Alabama
Mobile, Alabama, 36688
United States
Beckman Research Institute of City of Hope
Duarte, California, 91010
United States
VA Medical Center, Fresno
Fresno, California, 93703
United States
Santa Clara Valley Medical Center
Fruitdale, California, 95128
United States
St Jude Heritage Medical Group
Fullerton, California, 92835
United States
Oncology Institute for Hope and Innovation
Los Angeles, California, 90017
United States
Sacramento VA Medical Center - VA Northern California Health Care System
Mather, California, 95655
United States
Pacific Cancer Care
Monterey, California, 93940
United States
VA Palo Alto
Palo Alto, California, 94305
United States
Zuckerberg San Francisco General
San Francisco, California, 94110
United States
Kaiser Foundation Research Institute
San Francisco, California, 94115
United States
University of San Francisco
San Francisco, California, 94117
United States
San Francisco VA Medical Center
San Francisco, California, 94121
United States
Spark M. Matsunaga VA Medical Center
Honolulu, Hawaii, 96819
United States
North Las Vegas VA Medical Center
Las Vegas, Nevada, 89086
United States
George E. Wahlen Department of Veterans Affairs Medical Center
Salt Lake City, Utah, 84148
United States

Collaborators and Investigators

Sponsor: Stanford University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-24
Study Completion Date2028-02-28

Study Record Updates

Study Start Date2022-06-24
Study Completion Date2028-02-28

Terms related to this study

Keywords Provided by Researchers

  • Carcinoma
  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Melanoma
  • Pancreatic Neoplasms
  • Sarcoma
  • Ovarian Neoplasms
  • Carcinoma, Ovarian Epithelial
  • Stomach Neoplasms
  • Glioblastoma
  • Rectal Neoplasms
  • Colonic Neoplasms
  • Esophageal Neoplasms
  • Breast Neoplasms
  • Carcinoma, Renal Cell
  • Skin Neoplasms
  • Small Cell Lung Carcinoma
  • Osteosarcoma
  • Myelodysplastic Syndromes
  • Disease Progression
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Neoplasms
  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Lung Diseases
  • Respiratory Tract Diseases
  • Urogenital Neoplasms
  • Carcinoma, Bronchogenic

Additional Relevant MeSH Terms

  • End of Life
  • Cancer